Obsidian Therapeutics (OBX) AI Stock Analysis

• Market Cap: $18.11M
• Dividend Yield: N/A
• Average Volume (3M): 63.57K
• Price to Earnings (P/E): <0.1
• Beta (1Y): 1.95
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,040,118
• 10 Day Avg. Volume: 87,114
• 30 Day Avg. Volume: 63,573
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.36
• Enterprise Value/Market Cap: <0.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: $42.00
• Price Target Upside: 209900.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $35.00 ▲(174900.00% Upside)
• Action: Reiterated
• Date: 08/05/26

Positive Factors

Leverage eliminated

Removing debt and restoring positive equity materially reduces solvency risk and interest obligations, improving financial flexibility. This reset lets management allocate capital to clinical development and operations without near-term creditor pressure, strengthening survival odds through milestone-driven value creation.

Negative Factors

Pre-revenue operations

With no product revenue, the company remains dependent on financing and successful clinical outcomes to achieve commercial sustainability. Operating profitability and cash generation cannot be assumed until products are approved and adopted, keeping commercialization and execution risk high for the foreseeable term.

Obsidian Therapeutics Business Overview & Revenue Model

Company Description

A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technolo...

Read more

A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technolo...

How the Company Makes Money

null...

Obsidian Therapeutics Financial Statement Overview

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Obsidian Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBX, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 18.69, below the 50-day MA of 18.51, and below the 200-day MA of 11.04, indicating a bullish trend. The MACD of 2.24 indicates Negative momentum. The RSI at 68.95 is Neutral, neither overbought nor oversold. The STOCH value of 42.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OBX.

Obsidian Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OBX	53 Neutral	$18.11M	0.05	-210.64%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LGVN	46 Neutral	$22.17M	-0.61	-202.41%	―	-45.35%	58.32%
PASG	43 Neutral	$14.36M	-0.38	-150.88%	―	―	42.29%
CELU	42 Neutral	$18.39M	-0.17	411.46%	―	-51.03%	-35.20%
MRKR	41 Neutral	$18.84M	-1.69	-73.29%	―	-43.86%	49.21%
GTBP	40 Underperform	$13.01M	-0.05	-901.32%	―	―	-152.00%

Obsidian Therapeutics Corporate Events